Compare · COR vs SCNX
COR vs SCNX
Side-by-side comparison of Cencora Inc. (COR) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- COR is the larger of the two at $59.91B, about 3561.3x SCNX ($16.8M).
- COR has been more active in the news (7 items in the past 4 weeks vs 1 for SCNX).
- COR has more recent analyst coverage (25 ratings vs 0 for SCNX).
- Company
- Cencora Inc.
- Scienture Holdings Inc.
- Price
- -
- -
- Market cap
- $59.91B
- $16.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 0
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
Latest COR
- Executive Vice President Battaglia Silvana was granted 58 shares, increasing direct ownership by 0.25% to 23,624 units (SEC Form 4)
- Executive Vice President Campbell Elizabeth S was granted 50 shares, increasing direct ownership by 0.16% to 30,756 units (SEC Form 4)
- Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release
- SEC Form 4 filed by Chief Financial Officer Boratto Eva C
- New insider Boratto Eva C claimed ownership of 3 shares (SEC Form 3)
- Director Tyler Lauren M bought $148,626 worth of shares (550 units at $270.23), increasing direct ownership by 14% to 4,359 units (SEC Form 4)
- Director Durcan Dermot Mark bought $1,096,760 worth of shares (4,000 units at $274.19), increasing direct ownership by 14% to 31,767 units (SEC Form 4)
- SEC Form 11-K filed by Cencora Inc.
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Announces Samantha Hammock as Chief Human Resources Officer
Latest SCNX
- SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
- SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
- SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
- SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports First Quarter 2026 Financial Results and Business Update Highlighted by Significant Revenue Growth and Gross Margin Expansion
- SEC Form 10-Q filed by Scienture Holdings Inc.
- Scienture Secures $11.0 Million in Non-Dilutive Debt Financing to Accelerate Growth of Approved Product Portfolio and Advancement of R&D Pipeline